INTRODUCTION
In the absence of an HLA identical sibling, an HLA-A, -B, -C and -DRB1-matched unrelated donor (8/8 URD) is the best-established donor option for patients with high-risk hematological malignancies who need hematopoietic cell transplantation (HCT). However,~30% of Caucasian and 70-94% of African-American patients are unable to find an 8/8 URD. 1 A single antigen or allele HLA mismatch results in~10% worse absolute 5-year survival and greater risk of GvHD for patients with early-stage hematological malignancies compared with an 8/8 URD-HCT. [2] [3] [4] [5] Alternatives to mismatched unrelated donors include haploidentical donors and umbilical cord blood [6] [7] [8] but these may have higher rates of relapse and delayed engraftment, respectively.
Considerable interest has emerged in identifying more tolerable or permissive HLA mismatches or, conversely, HLA mismatches to avoid between patients and their unrelated donors to minimize adverse consequences of HLA mismatching. Numerous factors may determine the effect of specific HLA mismatches, considering that alleles differ in the number, type and location of amino-acid substitutions (AASs) in the structure of the HLA molecule, and their impact on peptide binding and T-cell allorecognition may be critical in determining transplant outcomes. Non-permissive AASs have been identified using both in vitro structure-function studies 9, 10 and outcome studies. [11] [12] [13] [14] We hypothesized that we could establish a subset of AAS associated with worse HCT outcomes. In 2012, our group reported a set of AAS that were associated with worse 100-day survival in single HLA-class I mismatched recipient-donor pairs compared with 8/8 URD pairs. 15 We now extend the analysis to include all AAS positions and amino-acid substitution and position types (AASPTs) and 1-year transplant and grades III-IV GvHD outcomes in separate training and validation data sets.
MATERIALS AND METHODS Patients Study end points
End points of this study were overall survival (OS), disease-free survival (DFS) and treatment-related mortality (TRM) at 1-year and severe (grades III-IV) acute GvHD by day 100. These outcomes were dichotomized for the random forest (RF) and logistic regression analyses and treated as time-to-event outcomes in the survival analyses as described below.
Statistical analyses RF analysis. The RF method, which grows a collection of classification trees, is a combination classifier and has been previously described. 15, 16 Briefly, the RF method is an extension of Classification and Regression Trees, which is used to discover relationships among a large number of predictor variables and a categorical or continuous outcome variable. Models were created that included four patient-donor clinical characteristics generally known to be associated with transplant outcomes (recipient age, gender match, type of disease and disease stage) and all HLA-A, -B and -C AASPT (n = 389 candidate AASPT) as predictor variables.
The procedure ranks all predictor variables in terms of an importance score (IS). In our previous publication, 15 we chose an IS cutoff of ⩾ 3 to indicate potentially important AASs; here a more conservative IS of 5 or greater was selected as the threshold. Note that the IS does not, by itself, indicate the statistical significance nor even the direction of the effect. The analysis was performed using commercially available software (Salford Systems, Version 6, San Diego, CA, USA).
Multivariate logistic regression analysis. To determine the direction and statistical significance of the effect of each AASPT on each clinical outcome, we performed multivariate logistic regression adjusted for the same four clinical variables mentioned above, that is, each model included five predictor variables. To avoid sparse data, we limited the logistic regression to the AASPT present in at least 10 individuals, thereby reducing the number of candidate AASPT from 389 to 155. The odds ratio for the given AASPT relative to 8/8 URD was determined and the average marginal effect for each outcome was estimated by computing a marginal probability from the fitted logistic regression model using Stata (version Survival analysis. The Kaplan-Meier 17 method was used to estimate OS and DFS rates according to risk groups (high-risk (presence of one or more high-risk AASPT), non-high-risk (mismatch but no high-risk AASPT) and 8/8 URD), defined on the basis of the RF and multivariate logistic regression analyses as described above. Comparison among the three groups was performed using the Cox proportional-hazards (PH) model. 18 All patients without an event were censored at 1 year. Cox regression was also performed to estimate cause-specific hazard ratios for TRM and GvHD. For TRM, patients who died from disease relapse were censored at the time of death, and for acute GvHD, all deaths in the absence of prior GvHD were treated as censored observations. Finally, cumulative incidence curves 19 were generated to estimate the incidence rates of acute GvHD, with death in the absence of acute GvHD as a competing event. All models were adjusted for the four patient-donor clinical characteristics.
Validation analyses. The validation analysis tested the AASPT discovered in the analysis of the training set directly in the validation cohort. Of note, identified high-risk AASPT varied for each outcome in the training data set. The AASPTs were therefore tested in the validation cohort in two ways. First, outcome-specific AASPTs were created with a trichotomous indicator variable for whether the donor/recipient pair had a high-risk AASPT, non-high-risk AASPT or were 8/8 matched for the specific outcome. A second test of the AASPT was based on an aggregated AASPT indicator variable which defines 'high-risk' as the presence of any of the AASPT identified as important for any of the four outcomes. This aggregated AASPT variable reflected the clinical reality that, if possible, transplant centers are likely to avoid donors with a high-risk AASPT for any adverse outcome.
We used the Cox proportional-hazards model to evaluate the association between risk groups and each outcome controlling for outcome-specific significant clinical variables that were identified based on the validation cohort instead of limiting adjustment to the previously identified four clinical variables. The outcome-specific models were constructed using a stepwise selection procedure with a threshold of 0.05 for both entry and removal, and the final set of adjustment clinical variables differed from the training cohort. As above, both the outcome-specific and aggregate definitions of high-risk AASPT were tested separately based on these models. Because of multiple testing, Po 0.01 was considered statistically significant. All reported P-values are two-sided. Analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Identifying high-risk AASPT and risk groups in the training set Based on the criteria of AASPT present in at least 10 individuals (n4 = 10), IS4 = 5 from RF, odds ratio41 (that is, a detrimental effect) and P o = 0.01 from logistic regression, the analysis discovered 19 high-risk AASPT, shown in Table 2 . Among them, only C97_WR was classified as high risk for all four outcomes. Given each list, we then stratified patients into three categories: (1) high-risk group included patients with at least one of the identified high-risk AASPT for that outcome; (2) non-high-risk group if they had any of the remaining AASPT including AASPT where n o 10 and (3) 8/8 URD. The complete list of AASPT with IS4 = 5 or P o = 0.01, including predicted event rates, is provided in the Supplementary Appendix, ST1.
High-risk AASPT for OS. We observed that seven AASPTs were associated with significantly increased mortality as compared with the 8/8 URD group (hazard ratio (HR) = 1.92; 95% confidence interval (CI) = 1.55-2.37) and the non-high-risk group (HR = 1.58; 95% CI = 1.25-2.01) as shown in Figure 1a (left-hand side).
High-risk AASPT for DFS. The estimated 1-year event rate for 8/8 URD pairs was 50.7%. Only three AASPTs met high-risk criteria. Figure 1c shows Kaplan-Meier curves according to AASPT risk groups.
High-risk AASPT for TRM. Eight AASPTs were significantly associated with an increased risk of TRM. High-risk group had significantly higher TRM than the non-high-risk group (HR = 1.42; 95% CI = 1.13-1.78) and 8/8 URD group (HR = 1.70; 95% CI = 1.40-2.06).
High-risk AASPT for acute GvHD grades III-IV. A total of seven AASPTs were identified as risk factors for severe acute GvHD by High-risk AASPT defined by the training data set. Abbreviations: CI = confidence interval; IS = importance score from random forest analysis; OR = odds ratio; 1Y = 1 year.
High-risk HLA-class I amino-acid substitutions in HCT SR Marino et al day 100. AAS C97_WR was again identified as a high-risk factor similar to the results for the other three HCT outcomes, whereas the other six AASPTs were uniquely identified as risk factors for acute GvHD. The HR for the high-risk group relative to the 8/8 URD was 1.72 (95% CI = 1.38-2.15; P o0.0001) and the HR for the nonhigh-risk group relative to 8/8 URD was 1.40 (95% CI = 1.15-1.70; P = 0.0009). Validation of high-risk AASPT Of 155 AASPTs present in at least 10 individuals in the training set, a total of 19 were identified as high-risk across all four outcomes. Only these 19 AASPTs were considered when analyzing the validation set. Of these 19, all but 2 (C156_QR and C116_YL) were present in at least 10 individuals in the validation set. Note, however, that in the validation analysis, patients were grouped as 'high risk' if they had any one of the high-risk AASPTs found in the training set.
Outcome-specific analysis in the validation cohort. Table 3 shows the results for the outcome-specific analyses in the validation cohort. Presence of at least one high-risk AASPT relative to HLA mismatch without a high-risk AASPT was not associated with OS, DFS, TRM or grade III-IV acute GvHD (all P40.33). As expected, HLA mismatch had inferior outcomes relative to 8/8 MUD, irrespective of the presence or absence of high-risk AASPT defined by the training data set. Figure 1b shows survival and Figure 1d shows DFS Kaplan-Meier curves according to AASPT risk groups. Figure 2b shows cumulative incidence curves for the validation cohort. All curves are adjusted for recipient age, gender match, type of disease and disease stage.
Aggregate analysis in the validation cohort. Table 4 shows the aggregate analysis results in the validation cohort comparing high-risk AASPT for any outcome to only non-high-risk AASPT. Presence of at least one high-risk AASPT for any outcome was not associated with OS, DFS, TRM, or grade III-IV acute GvHD related to non-high-risk AASPT.
DISCUSSION
We sought to identify and validate high-risk class I HLA AASPT for 1-year outcomes and grade III-IV acute GvHD after allogeneic transplants. To accomplish this, we used two independent recipient-donor populations, training data set 1988-2004, predominantly bone marrow, and a more recent validation data set (2004-2011), predominantly peripheral blood stem cells as donor sources, and employed a novel statistical approach using RF and logistic regression methods in a large and homogeneous group of patients with hematological malignancies to define AASPT associated with worse outcomes. AASPT C97_WR (patient-donor, respectively) showed greater risks across all outcomes and AASPT C80_NK, C77_SN and C156_RW conferred greater risks in more than one end point. These results are consistent with day 100 survival results previously reported from our group, 15 Table 5 , as well as with previous reports from the literature. 11, 12, 14 The training set was the same as our prior analysis but extended to 1-year outcomes. We tested our results in an independent cohort from a more recent era for validation. Although a similar trend in the validation results was observed (Figures 1 and 2) , we did not confirm that the specific AASPT found in the training set were significantly associated with any of the tested outcomes in the validation cohort.
Evaluation of permissiveness of HLA mismatches has been an area of interest in the field of HCT for over a decade and by using approaches based on a biological hypothesis and experimental data, some permissive HLA alleles have been identified and validated in independent data sets, that is, HLA-DPB1 T-cell-epitope groups [20] [21] [22] as well as HLA-C*03:03 versus HLA-C*03:04. 23, 24 Several groups have studied HLA non-permissiveness using other approaches. In regards to high-risk AASPT at HLA-class I loci, review of the literature indicates that no classification scheme has been validated in an independent data set. 11, 12, 14, [25] [26] [27] [28] It is noteworthy that our results from the training data set were consistent with results from Ferrara et al. 11 and Kawase et al.,
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even though those studies were performed in heterogeneous populations that included both patients with advanced hematological malignancies and patients with non-malignant diseases.
In particular, AAS HLA-C-116, located in the F pocket of the peptide-binding region, 29 has been consistently been identified as high risk in outcome studies 11, 12, 14, 15 as well as in cellular assays. 30 A number of other CIBMTR studies testing proposed algorithms for categorizing mismatches were unsuccessful when applied to HCT data. [25] [26] [27] [28] Approaches to categorizing mismatches varied using serologically defined cross-reactive epitopes, Figure 2 . Adjusted cumulative incidence estimates of acute GvHD by day 100 after transplantation according to the three (matched, high-risk and non-high-risk) groups. a: training cohort; b: validation cohort. 27 and the Histocheck algorithm. 28, 31, 32 Therefore, at the present time despite substantial effort, suitability of HLA mismatched unrelated donors cannot be predicted with a few exceptions. We believe that the main reasons why results from training data sets fail to be validated in independent data sets can be grouped into two categories: (1) differences in analyzed data sets, (2) complexity of the problem and/or inadequacy of statistical approaches used. First, in the case of our study, the training and testing data sets differed because transplant technologies evolved, that is, predominantly bone marrow transplants in the initial data set versus PBSCs in the discovery data set, and different conditioning regimens and GvHD prophylaxis were used. Because of how the study evolved, the training and testing sets were derived from two different eras of transplantation. Lack of validation of previous results using more modern data sets has been reported. 33, 34 Although a randomized analysis would remove population heterogeneity as a potential cause of failure to validate, it also fails to acknowledge that the goal of the testing set is to prove that results are robust enough to be applicable to future patients. Therefore, established algorithms of non-permissible mismatches need to be re-tested as clinical and transplant conditions evolve.
The second reason that initial observations are not validated in independent cohorts may be that robust identification of permissive or non-permissive HLA mismatches may not be a tractable problem given the size of the available analytic population, the analytic methods currently available, the blunt outcomes available to study and the complexity of the problem. It is likely that a combination of AASPT rather than single residues is associated with specific outcomes. In addition, our statistical approach is not based on a specific biological hypothesis and assumes that any AAS could potentially have comparable impact on outcomes. With multiple AASPT being responsible for outcomes, our ability to use traditional statistical models may not be sufficient because of the high number of variables and low number of cases for each of them. It is possible that genome-wide diversity affecting immune responses and other determinants of alloreactivity may also play a role on HCT outcomes. Therefore, investigation of novel methodological approaches is a highly desirable goal.
The complexity of donor-recipient incompatibility is the result of the exponential number of combinations that must be considered to evaluate risk stratification. Our group has explored a molecular modeling-based approach to simulate binding of peptides among mismatched recipient-donor pairs to predict high-risk versus non-high-risk groups. 35 Simulations such as these may be used to propose hypothesis-driven molecular modeling approaches, and results could then be validated experimentally, and statistically and then translated into clinical practice.
This study has some limitations. Only patients with HLA-A, -B, -C and -DRB1 typing have been studied. Therefore, the impact of the cumulative effects of HLA disparities in low-expression class II HLA loci 36 on HCT outcomes is unknown. In addition, the effect of non-permissive DPB1 T-cell epitope mismatching 21 has not been studied. Comparison of the high-risk AAS identified in this report with the high-risk AAS identified in our previous report (Marino et al.) This study Previous study (Marino et al. 15 Based on our results and review of the literature, we strongly recommend that initial observations are tested in independent cohorts and validation results follow the original observations. Although identification of an algorithm that can help stratify risk of specific recipient-donor mismatches is a desirable goal, it has proved difficult and elusive to date. Our results do not suggest that any particular AASPT in class I should be avoided based on OS, DFS, relapse or grade III-IV acute GvHD. Additional studies should be performed to fully understand the role of AASPT in HCT outcomes.
